These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 30294857)

  • 1. Assessment of plasma lactate and core-peripheral temperature gradient in association with stages of naturally occurring myxomatous mitral valve disease in dogs.
    Soares FB; Pereira-Neto GB; Rabelo RC
    J Vet Emerg Crit Care (San Antonio); 2018 Nov; 28(6):532-540. PubMed ID: 30294857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs.
    Nakamura K; Kawamoto S; Osuga T; Morita T; Sasaki N; Morishita K; Ohta H; Takiguchi M
    J Vet Intern Med; 2017 Mar; 31(2):316-325. PubMed ID: 28145607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between serum homocysteine concentration and severity of mitral valve disease in dogs.
    Lee CM; Jeong DM; Kang MH; Kim SG; Han JI; Park HM
    Am J Vet Res; 2017 Apr; 78(4):440-446. PubMed ID: 28345991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased serum C-reactive protein concentrations in dogs with congestive heart failure due to myxomatous mitral valve disease.
    Reimann MJ; Ljungvall I; Hillström A; Møller JE; Hagman R; Falk T; Höglund K; Häggström J; Olsen LH
    Vet J; 2016 Mar; 209():113-8. PubMed ID: 26831162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The diagnostic relevance of NT-proBNP and proANP 31-67 measurements in staging of myxomatous mitral valve disease in dogs.
    Wolf J; Gerlach N; Weber K; Klima A; Wess G
    Vet Clin Pathol; 2013 Jun; 42(2):196-206. PubMed ID: 23614733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron parameters analysis in dogs with myxomatous mitral valve disease.
    Kumiega E; A Kobak K; Noszczyk-Nowak A; Kasztura M
    BMC Vet Res; 2024 May; 20(1):210. PubMed ID: 38762716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Markers of Oxidative Stress in Dogs with Myxomatous Mitral Valve Disease are Influenced by Sex, Neuter Status, and Serum Cholesterol Concentration.
    Reimann MJ; Häggström J; Møller JE; Lykkesfeldt J; Falk T; Olsen LH
    J Vet Intern Med; 2017 Mar; 31(2):295-302. PubMed ID: 28132441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma and serum serotonin concentrations and surface-bound platelet serotonin expression in Cavalier King Charles Spaniels with myxomatous mitral valve disease.
    Cremer SE; Kristensen AT; Reimann MJ; Eriksen NB; Petersen SF; Marschner CB; Tarnow I; Oyama MA; Olsen LH
    Am J Vet Res; 2015 Jun; 76(6):520-31. PubMed ID: 26000599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonin concentrations in platelets, plasma, mitral valve leaflet, and left ventricular myocardial tissue in dogs with myxomatous mitral valve disease.
    Cremer SE; Singletary GE; Olsen LH; Wallace K; Häggström J; Ljungvall I; Höglund K; Reynolds CA; Pizzinat N; Oyama MA
    J Vet Intern Med; 2014; 28(5):1534-40. PubMed ID: 25146933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and their correlation with lipoproteins in dogs with myxomatous mitral valve disease.
    Khaki Z; Nooshirvani P; Shirani D; Masoudifard M
    BMC Vet Res; 2022 Dec; 18(1):448. PubMed ID: 36564735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression Profiling of Circulating MicroRNAs in Canine Myxomatous Mitral Valve Disease.
    Li Q; Freeman LM; Rush JE; Laflamme DP
    Int J Mol Sci; 2015 Jun; 16(6):14098-108. PubMed ID: 26101868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Symmetric dimethylarginine in dogs with myxomatous mitral valve disease at various stages of disease severity.
    Valente C; Guglielmini C; Domenech O; Contiero B; Zini E; Poser H
    PLoS One; 2020; 15(9):e0238440. PubMed ID: 32870923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomics reveals plasma protein SERPINH1 as a potential diagnostic biomarkers for myxomatous mitral valve disease stage B2.
    Zhou Q; Wu Z; Li L; Zhou H; Chen Y; Guo S; Guo Y; Ma X; Zhang J; Feng W; Cui X; Qiu C; Xu M; Deng G
    J Proteomics; 2023 Jun; 282():104924. PubMed ID: 37146676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biopterin status in dogs with myxomatous mitral valve disease is associated with disease severity and cardiovascular risk factors.
    Reimann MJ; Häggström J; Mortensen A; Lykkesfeldt J; Møller JE; Falk T; Olsen LH
    J Vet Intern Med; 2014; 28(5):1520-6. PubMed ID: 25274442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain-natriuretic peptide and cyclic guanosine monophosphate as biomarkers of myxomatous mitral valve disease in dogs.
    Moesgaard SG; Falk T; Teerlink T; Guðmundsdóttir HH; Sigurðardóttir S; Rasmussen CE; Olsen LH
    Vet J; 2011 Sep; 189(3):349-52. PubMed ID: 20822939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of plasma and urinary levels of 6-keto-prostaglandin F1alpha as a marker for asymptomatic myxomatous mitral valve disease in dogs.
    Rasmussen CE; Sundqvist AV; Kjempff CT; Tarnow I; Kjelgaard-Hansen M; Kamstrup TS; Sterup AL; Soerensen TM; Olsen LH
    Vet J; 2010 May; 184(2):241-6. PubMed ID: 19324577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors affecting the urinary aldosterone-to-creatinine ratio in healthy dogs and dogs with naturally occurring myxomatous mitral valve disease.
    Galizzi A; Bagardi M; Stranieri A; Zanaboni AM; Malchiodi D; Borromeo V; Brambilla PG; Locatelli C
    BMC Vet Res; 2021 Jan; 17(1):15. PubMed ID: 33413406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myxomatous mitral valve disease and associated pulmonary hypertension might increase serum angiopoietin-2 in dogs.
    Yu H; Lee D; Chae Y; Choi M; Lee Y; Yun T; Kang BT; Yang MP; Kim H
    Am J Vet Res; 2024 Jun; 85(6):. PubMed ID: 38531156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urine 5-hydroxyindoleacetic acid in Cavalier King Charles spaniels with preclinical myxomatous mitral valve disease.
    Christiansen LB; Cremer SE; Helander A; Madsen T; Reimann MJ; Møller JE; Höglund K; Ljungvall I; Häggström J; Olsen LH
    Vet J; 2019 Aug; 250():36-43. PubMed ID: 31383418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral blood lymphocyte subtypes in dogs with different stages of myxomatous mitral valve disease.
    Druzhaeva N; Nemec Svete A; Ihan A; Pohar K; Domanjko Petrič A
    J Vet Intern Med; 2021 Sep; 35(5):2112-2122. PubMed ID: 34236111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.